On August 18, 2023, Haoyue Capital, a leading investment firm focusing on China's healthcare industry, released its "Seventh Annual list for Outstanding Healthcare Investment". RECORNA Bio was honored with the 2022 Best Innovative Pharmaceutical Company award.
As a highly recognized annual authoritative ranking in the industry, the Outstanding Healthcare Investment Honor Roll, first launched in 2017, has always adhered to the principles of fairness, impartiality, and objectivity, through a real-name and one vote per firm voting process. Based on publicly disclosed information and data submitted by institutions, the list is generated by comprehensively evaluating companies’ investment activity, transaction volume, transaction value, and investment returns. This process identifies outstanding investment institutions for the year. Additionally, the Outstanding Honor Roll awards excellence in various healthcare sectors, including Innovative Pharmaceuticals, Innovative Medical Devices, IVD and Life Science, Medical Services, and Smart Healthcare. The aim is to establish a credible and influential investment ranking that sets new industry benchmarks and creates new investment opportunities.
RECORNA Bio is a biotechnology company committed to developing groundbreaking RNA-targeted therapy. The company has established a proprietary RNA-base editing platform protected with intellectual property rights. Through leveraging the endogenous adenosine deaminase (ADAR, an enzyme that catalyzes A-to-I RNA editing in the body), our drug molecules can achieve precise and efficient RNA base editing. This technology enables the restoration and/or enhancement of proteins’ functional properties and/or output, yet without permanent modification of the genome. This innovation places RECORNA at the forefront of the field, both nationally and globally.
As a leading company for the development of RNA editing therapeutics, RECORNA Bio remains committed to its mission of harnessing the potential of RNA editing technology to develop innovative therapies for patients worldwide suffering from previously incurable diseases. As times advance, the future holds great promise. RECORNA Bio looks forward to working hand-in-hand with Haoyue Capital and other industrial peers to ride the wave of the momentum and to create new horizons, contributing to the steady development of China's healthcare industry.
